On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its ARO-MAPT program targeting Alzheimer's disease.

On the news front, the company's ARO-MAPT drug, developed on its proprietary TRiM BBB platform, utilizes siRNA conjugated to a transferrin receptor-targeting ligand delivered via subcutaneous injection to cross the blood-brain barrier and silence the MAPT gene across the entire brain for treatment of Alzheimer's disease and other tauopathies. Preclinical data demonstrated that ARO-MAPT achieved 70-80% mRNA knockdown in non-human primates, covering multiple cell types including neurons and astrocytes. This represents a significant validation of the company's blood-brain barrier delivery technology platform for CNS RNAi therapeutics.

Within the Biotechnology sector, individual stocks showed mixed performance. Among notable movers, uniQure NV up 76.77%, AbbVie down 0.13%, Gilead Sciences down 0.28%, Amgen down 0.18%, Nuvalent Inc. flat 0%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)